Aligning and constructing dialogue between industry, regulators and payers.
- At: 2010 FIP Congress in Lisbon (Portugal)
- Type: Presentation
- By: MARTINS, Ana Paula (Merck, Porto Salvo, Portugal)
New drugs had demonstrating a significant impact in health outcomes. This impact has led to longevity as well as increase of productivity in modern societies. The measurement of both added therapeutic value (risk-benefit compared to alternative therapies) and cost-benefit of new therapies have been requested in the Health Systems to decide whether.. The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress.